Wechselwirkungen von Methyltestosteron

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (Fachinformation zu Choriongonadotropin, Gegenanzeigen)

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (Fachinformation zu Doravirin, Gegenanzeigen)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (Fachinformation zu Finasterid, Gegenanzeigen)

To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. (Fachinformation zu Methyltestosteron, Warnhinweise)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Fachinformation zu Choriogonadotropin alfa, Vorsichtsmaßnahmen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Fachinformation zu Estradiol und Norethisteron, Warnhinweise und Vorsichtsmaßnahmen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. (Fachinformation zu Follitropin, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Fachinformation zu Goserelin, Warnhinweise und Vorsichtsmaßnahmen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Fachinformation zu Konjugierte Estrogene, Vorsichtsmaßnahmen)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Fachinformation zu Konjugierte Estrogene und Bazedoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (Fachinformation zu Leuprorelin, Warnhinweise und Vorsichtsmaßnahmen)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nictonic Acid These drugs may decrease serum TBG concentration. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (Fachinformation zu Lovastatin, Arzneimittelwechselwirkungen)

The following laboratory tests may be affected by progestins including MPA Injectable Suspension, USP: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (Fachinformation zu Medroxyprogesteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (Fachinformation zu Ramelteon, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (Fachinformation zu Spironolacton und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (Fachinformation zu Tamoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Fachinformation zu Methyltestosteron, Warnhinweise)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (Fachinformation zu Triptorelin, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Methyltestosteron, Vorsichtsmaßnahmen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Methyltestosteron, Vorsichtsmaßnahmen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Methyltestosteron, Vorsichtsmaßnahmen)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Methyltestosteron, Vorsichtsmaßnahmen)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)